Immunovant (IMVT) Depreciation & Amortization (CF) (2019 - 2026)
Immunovant (IMVT) posted Depreciation & Amortization (CF) of $96000.0 for Q1 2026, down 4.95% on a QoQ basis from $101000.0 in Q4 2025, and down 11.93% year-over-year from $109000.0 in Q1 2025.
Immunovant (IMVT) Depreciation & Amortization (CF) (2019 - 2026) Analysis & Trends
Immunovant's Depreciation & Amortization (CF) history runs 8 years deep, the most recent figure standing at $96000.0 for Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 11.93% year-over-year to $96000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $409000.0 (up 8.49% YoY) and the FY2026 annual result came in at $409000.0, up 8.49% from the prior year.
- Depreciation & Amortization (CF) was $96000.0 for Q1 2026 at Immunovant, down from $101000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $109000.0 in Q1 2025 and bottomed at $39000.0 in Q1 2022.
- A 5-year average of $73470.6 and a median of $64000.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) soared 77.27% — and 2026, when it dropped 11.93%.
- Immunovant's Depreciation & Amortization (CF) stood at $49000.0 in 2022, then increased by 18.37% to $58000.0 in 2023, then jumped by 70.69% to $99000.0 in 2024, then increased by 2.02% to $101000.0 in 2025, then declined by 4.95% to $96000.0 in 2026.
- Business Quant data shows IMVT's Depreciation & Amortization (CF) at $96000.0 in Q1 2026, $101000.0 in Q4 2025, and $105000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Immunovant | 7.18 Bn | 7.18 Bn | - | 96,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 96,000.00 |
| Mar 31, 2026 | 96,000.00 |
| Dec 31, 2025 | 101,000.00 |
| Dec 31, 2025 | 101,000.00 |
| Sep 30, 2025 | 105,000.00 |
| Sep 30, 2025 | 105,000.00 |
| Jun 30, 2025 | 107,000.00 |
| Jun 30, 2025 | 107,000.00 |
| Mar 31, 2025 | 109,000.00 |
| Mar 31, 2025 | 109,000.00 |
| Dec 31, 2024 | 99,000.00 |
| Dec 31, 2024 | 99,000.00 |
| Sep 30, 2024 | 89,000.00 |
| Sep 30, 2024 | 89,000.00 |
| Jun 30, 2024 | 80,000.00 |
| Jun 30, 2024 | 80,000.00 |
| Mar 31, 2024 | 64,000.00 |
| Mar 31, 2024 | 64,000.00 |
| Dec 31, 2023 | 58,000.00 |
| Dec 31, 2023 | 58,000.00 |